Meeting
2021 ASCO Annual Meeting
Adjuvant capecitabine in locoregionally advanced nasopharyngeal carcinoma: A multicenter randomized controlled phase III trial.
Presenter
Jingjing Miao, MSc
Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Oral Abstract Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Local-Regional Disease
Clinical Trial Registration Number
NCT02143388
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 6005)
DOI
10.1200/JCO.2021.39.15_suppl.6005
Abstract #
6005
Abstract Disclosures
Similar Videos & Slides
Videos & Slides
2021 ASCO Annual Meeting
Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: A phase 3, multicenter, randomized controlled trial.
Speaker: Jun Ma
Videos & Slides
2024 ASCO Annual Meeting
Endostar combined with concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone for locoregionally advanced nasopharyngeal carcinoma (LA-NPC): A phase III, prospective, randomised-controlled, multicenter clinical trial.
Speaker: Min Kang, MD
Videos & Slides
2024 ASCO Annual Meeting
Adjuvant PD-1 blockade with camrelizumab in high-risk locoregionally advanced nasopharyngeal carcinoma (DIPPER): A multicenter, open-label, phase 3, randomized controlled trial.
Speaker: Xu Liu, MD
Videos & Slides
2023 ASCO Annual Meeting
Induction chemotherapy plus radiotherapy alone versus cisplatin-based concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: An open-label, non-inferiority, randomized phase 3 trial.
Speaker: MingYuan Chen, MD&PhD